- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS - Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS SOUTH SAN...

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq:...

Collaboration focused on helping repairers easily identify OEM-recommended calibrations for collision-damaged vehicles equipped with Advanced Driver-Assistance Systems (ADAS) SAN DIEGO and...

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid nanoparticle (LNP) delivery solutions for oncology...

Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses,...

Exactech, a global medical technology leader, will showcase its advanced vitamin E polyethylene and latest total joint replacement innovations at Booth #1218 at the American Association of Hip and...

Neogen® Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 2024 UBS Global Healthcare Conference in Rancho Palos Verdes, California, on Tuesday, November 12....

Vantiq, the leading software platform for building and operating intelligent systems, announced today that executive David Sprinzen will speak at the Smart City Expo World Congress in Barcelona,...